Impact of definitive therapy with Beta-Lactam monotherapy or combination with an Aminoglycoside or a Quinolone for pseudomonas aeruginosa bacteremia

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bliziotis, Ioannis A ^a   Petrosillo, Nicola ^b   Michalopoulos, Argyris ^a,c   Samonis, George ^d   Falagas, Matthew E ^a,c,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c HENRY DUNANT HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFPIROME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OXACILLIN; PEFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GREECE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; TERTIARY HEALTH CARE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; EVALUATION; METHODOLOGY; MULTICENTER STUDY; STANDARD; TREATMENT OUTCOME;

PSEUDOMONAS AERUGINOSA;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HUMANS; PSEUDOMONAS AERUGINOSA; QUINOLONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80055047937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026470     Document Type: Article

References (43)

1. Blot S, Vandewoude K, Hoste E, Colardyn F, (2003) Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J Hosp Infect 53: 18-24.
2. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP, (2011) Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66: 175-179.
3. Osmon S, Ward S, Fraser VJ, Kollef MH, (2004) Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 125: 607-616.
4. Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB, (2010) Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 38: 25-32.
5. Vitkauskiene A, Skrodeniene E, Dambrauskiene A, Macas A, Sakalauskas R, (2010) Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality. Medicina (Kaunas) 46: 490-495.
6. Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, et al. (2010) Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 54: 3590-3596.
7. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, et al. (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54: 3717-3722.
8. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, et al. (2011) Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 39: 46-51.
9. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, et al. (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51: 3510-3515.
10. Todeschini G, Franchini M, Tecchio C, Meneghini V, Pizzolo G, et al. (1998) Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 3: 99-104.
11. Bodey GP, Jadeja L, Elting L, (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145: 1621-1629.
12. Flick MR, Cluff LE, (1976) Pseudomonas bacteremia. Review of 108 cases. Am J Med 60: 501-508.
13. Harbarth S, Nobre V, Pittet D, (2007) Does antibiotic selection impact patient outcome? Clin Infect Dis 44: 87-93.
14. Mutlu GM, Wunderink RG, (2006) Severe pseudomonal infections. Curr Opin Crit Care 12: 458-463.
15. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME, (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41: 149-158.
16. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L, (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328: 668.
17. Clark NM, Patterson J, Lynch JP 3rd, (2003) Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 9: 413-423.
18. Lopez-Dupla M, Martinez JA, Vidal F, Almela M, Soriano A, et al. (2009) Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control 37: 753-758.
19. Niederman MS, (2001) Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 29: N114-120.
20. Waterer GW, Wunderink RG, (2001) Increasing threat of Gram-negative bacteria. Crit Care Med 29: N75-81.
21. Falagas ME, Matthaiou DK, Bliziotis IA, (2006) The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57: 639-647.
22. Paul M, Leibovici L, (2005) Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 5: 192-193; discussion 193-194.
23. Safdar N, Handelsman J, Maki DG, (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4: 519-527.
24. Chamot E, Boffi El Amari E, Rohner P, Van Delden C, (2003) Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47: 2756-2764.
25. Siegman-Igra Y, Ravona R, Primerman H, Giladi M, (1998) Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 2: 211-215.
26. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, et al. (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156: 2121-2126.
27. Annane D, Bellissant E, Cavaillon JM, (2005) Septic shock. Lancet 365: 63-78.
28. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, et al. (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32: 1249-1272.
29. Charlson M, Szatrowski TP, Peterson J, Gold J, (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47: 1245-1251.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
31. Khan NF, Perera R, Harper S, Rose PW, (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11: 1.
32. Forum TIS, (2001) Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 27 (Suppl 1): S1-134.
33. Davies CW, Gleeson FV, Davies RJ, (2003) BTS guidelines for the management of pleural infection. Thorax 58 (Suppl 2): ii18-28.
34. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, et al. (2002) The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt) 3: 161-173.
35. Institute CaLS (2005) Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
36. Standards NCfCL Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, sixth edition: 2003. In Approved standard M7-A6. NCCLS, Wayne, PA; 2003.
37. Falagas ME, Kouranos VD, Michalopoulos A, Rodopoulou SP, Athanasoulia AP, et al. Inadequate statistical power of published comparative cohort studies on ventilator-associated pneumonia to detect mortality differences. Clin Infect Dis 50: 468-472.
38. Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, et al. (2008) Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 27: 1219-1225.
39. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, et al. (2005) Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect 11: 415-418.
40. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, et al. (2005) Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49: 1306-1311.
41. Koprnova J, Beno P, Korcova J, Mrazova M, Grey E, et al. (2005) Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic. J Chemother 17: 470-476.
42. Vidal F, Mensa J, Martinez JA, Almela M, Marco F, et al. (1999) Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 18: 473-477.
43. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, et al. (2000) Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 160: 501-509.